MEMORY PHARMACEUTICALS COMMENCES TRIAL OF MEM 1003

A A

Memory Pharmaceuticals announced the dosing of the first patient in a Phase IIa clinical trial of MEM 1003 in patients with mild-to-moderate Alzheimer's disease.

The Phase IIa clinical trial is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of two dose levels of MEM 1003 in approximately 180 patients with mild-to-moderate Alzheimer's disease at approximately 50 centers.

Patients participating in the study will be randomized at enrollment into one of three treatment groups -- 30 mg of MEM 1003 twice a day, 90 mg of MEM 1003 twice a day or placebo twice a day. During the double-blind treatment segment of the study, patients will receive MEM 1003 or placebo for a period of 12 weeks, which will be followed by a four-week single-blind placebo treatment.